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Comprehensive evaluation of the upstream sensory processing in diabetic symmetrical 
polyneuropathy (DSPN) is sparse. We investigated the spinal nociceptive withdrawal reflex 
(NWR), and the related elicited somatosensory evoked cortical potentials. We hypothesized 
that DSPN induces alterations in spinal and supra-spinal sensory-motor processing 
compared to age- and gender matched healthy controls.  
Methods  
In this study 48 patients with type-1 diabetes and DSPN were compared to 21 healthy 
controls. Perception- and reflex-threshold were determined and subjects received electrical 
stimulations on the plantar site of the foot at three stimulation intensities to evoke a NWR. 
EMG and EEG were recorded for analysis. 
Results 
Patients with DSPN had higher perception- (p<0.001) and reflex- (p=0.012) threshold. Fewer 
patients completed the recording session compared to healthy (34/48 vs 21/21; p<0.004). 
DSPN reduced the odds ratio (OR) of a successful elicited NWR; (OR=0.045; p=0.014). DSPN 
changed the evoked potentials (F=2.86; p=0.025), and post hoc test revealed reduction of 
amplitude (-3.72mV; p<0.021) and prolonged latencies (15.1 ms; p<0.013) of the N1 peak. 
Conclusions 
The study revealed that patients with type-1 diabetes and DSPN have significantly changed 
spinal and supraspinal processing of the somatosensory input. This implies that DSPN 
induces widespread differences in the central nervous system processing of afferent A-δ and 
A-β fiber input. These differences in processing may potentially lead to identification of 
3 
 
subgroups with different stages of small fiber neuropathy and ultimately differentiated 
treatments. 
 





The prevalence of diabetes mellitus (DM) is increasing (1,2). Consequently, microvascular 
complications accompanying long-term DM have become more common, and among the 
most serious is diabetic neuropathy (3). Classically, diabetic neuropathy manifests as length 
dependent diabetic symmetrical polyneuropathy (DSPN), which affects the long nerve fibres 
in the body and commonly presents symptoms in the feet and hands (4,5). Approximately 
30-50% who suffer from type-1 or -2 DM will develop diabetic neuropathy (5–7). These 
alterations are typically measured by nerve conduction studies (8) which, among other 
assessments of nerve fibre functionality, are used to diagnose DSPN (8). To obtain a more 
comprehensive evaluation of the upstream sensory processing in DSPN, somatosensory 
evoked potentials (SEPs) have been recorded following electrical stimulation of the median 
and tibial nerves (9,10). Prolonged latencies of the SEPs have been associated to disease 
duration, motor nerve conduction velocity (11) and peripheral nerve dysfunction (9). 
Reduced SEP amplitudes were shown in studies based on median nerve stimulation, 
indicating axonal loss, and consequently affected conduction response in the central as well 
as peripheral somatosensory pathways (10).  
The nociceptive withdrawal reflex (NWR) is a spinal polysynaptic reflex that integrates 
sensory input to escape a potential harmful stimulation (12). The NWR can be elicited from 
the plantar side of the foot. In contrast to studies of nerve conduction which measures A-β 
fiber response, the NWR is primarily mediated by A-δ- and C -fibers (13). In this study, we 
wanted to investigate how DSPN affects spinal and supra-spinal sensory-motor processing. 
Therefore, as a proxy of the spinal sensory transmission, we recorded the NWR to electrical 
stimulation and concomitantly recorded SEPs at the scalp surface, to measure supra-spinal 
processing of the same stimulus. 
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We hypothesized that long-term DM induces alterations in spinal and supra-spinal sensory-
motor processing compared to age- and gender matched healthy controls. Therefore, the 
primary objective of the present study was to characterize neuronal response at the spinal 
and supra-spinal levels in people with long-term DM and verified DSPN compared to healthy 
controls. 
Thus, the aims of the study were to compare: I) ability to elicit an NWR measured as 
numbers of reflexes, II): quantifications of the NWR using latency and area under the curve 
(AUC) of the EMG response and III): SEP measured close to the brainstem (Oz), and the 






Forty-eight patients with DM were recruited at the Department of Endocrinology, Aalborg 
University Hospital, Denmark. Potential eligible patients were pre-screened based on a 
recorded vibration perception thresholds above 18 V. DSPN was verified by nerve 
conduction tests, according to the Toronto criteria (8). Additional inclusion criteria were age 
above 18 years, a verified diagnosis of type-1 DM for a minimum of 2 years: (hemoglobin 
A1c (HbA1c) level ≥6.5% [>48 mmol/mol]), stable hyperglycemic medication, and body mass 
index>22 kg/m2. Exclusion criteria included type-2 DM, other neurological disorders than 
DSPN, estimated glomerular filtration rate <60 ml/min/1.73m2, calcitonin >25 ng/l, HbA1c 
level <6.5%, use of glucagon-like peptide-1 agonists or dipeptidyl peptidase-4 inhibitors.  
Twenty-one age-matched healthy volunteers were included for comparison. Inclusion 
criteria were age above 18 years and normal peripheral nerve conduction. Exclusion criteria 
included type-1- and 2 DM, neurological disorders and medication that could alter neuronal 
function. 
Ethical approval was granted by Region Nordjylland, Denmark (N-20130077, N-20090008) 
and all participants gave written informed consent prior to entering the study. The study 
was registered in public databases (EUDRA CT, ref 2013-004375-12) and clinicaltrials.gov (ref 
NCT02138045) and was performed in accordance with International Council for 
Harmonization Good Clinical Practice and the Declaration of Helsinki. The experiment was 
conducted between June 2014 and January 2017 at Aalborg University Hospital.  
A visual representation of the data analysis steps and the number of subjects who were able 
to participate in the given parts of the study are shown in Figure 1.   
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----------------------------------------------- (Figure 1) around here--------------------------------------------- 
Experimental procedure  
Electrical stimulation 
Electrical stimulation of the plantar skin of the foot (innervation site of the medial plantar 
nerve) was applied through surface electrodes to evoke NWR´s of the foot and elicit SEPs. 
The cathode was placed in the arch of the sole of the right foot (15X15 mm, Neuroline 700; 
Ambu A/S, Copenhagen, Denmark). The anode was placed on the foot dorsum (50X90 mm, 
Synapse; Ambu A/S, Copenhagen, Denmark). The stimulus was delivered by a computer-
controlled electrical stimulator (Noxitest IES 230, Aalborg, Denmark) as a constant current 
burst of five rectangular-wave pulses, with 1 ms duration and 4 ms between pulses. A 
custom-made LABVIEW software (Center for Sensory-Motor Interaction, Aalborg University, 
Denmark) was used to control the stimulations. Subjects were positioned in an incline 
supine position and a pillow was placed under the knee to ensure relaxation in the leg 
muscles during stimulations. The perception threshold (PT) and NWR threshold (RT) were 
identified by increasing the stimulus intensity with increments of 1 mA. The PT corresponds 
to the stimulation intensity at which first sensation was felt. The RT was identified using the 
staircase method with 3 ascending and 3 descending threshold estimates. The ascending 
threshold was defined as the first reflex visible on EMG trace of the target muscle, and the 
descending threshold was 1 mA below the last stimulation to show a reflex visible on EMG. 
The RT was defined as the average of the 6 staircase end values. Once the RT was found, the 
subjects were asked to rate the pain intensity of the RT stimulations delivered at threshold 
(1.0 times RT), medium intensity (1.3 times RT) and high intensity (1.6 times RT) on a visual 
analogue scale, ranging from 0 to 10, where 0 means no pain and 10 is maximum imaginable 
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pain. Subsequently, 18 stimuli (six times each of the three intensities) were applied in 
random order with a varying inter-stimulus interval of 8-12 seconds. For safety reasons a 
threshold of 50 mA was set as a maximum intensity. If this threshold was crossed, or if 
pain/unpleasantness became unbearable the recording session was marked as incomplete 
and the highest stimulation intensity recorded was used to calculate RT.  
Nociceptive withdrawal reflex recordings 
Two surface electrodes (15X15 mm, Neuroline 700; Ambu A/S, Copenhagen, Denmark) were 
placed on the belly of the anterior tibial muscle ipsilateral to the site of stimulation, with an 
inter-electrode distance of 20 mm. The skin was lightly abraded before the electrodes were 
placed. A ground electrode (50X90 mm, Synapse; Ambu A/S) was placed distally to the 
patella of the ipsilateral knee. The EMG signals were sampled at 2000 Hz, and recorded 100 
ms before and 900 ms after the stimulation for analysis.  
Somatosensory evoked potential (SEP) recordings 
A 61 surface electrode EEG cap (MEQNordic A/S, Jyllinge, Denmark) was used. Conductive 
gel was applied to reduce the electrode impedance below 5 kΩ. During NWR stimulations, 
subjects were asked to relax with their eyes open. The SEP signals were recorded in 
continuous mode with a sampling rate of 1000 Hz (SynAmp; Neuroscan, El Paso, TX, USA) 






The EMG data was pre-processed using Matlab (R 2019a Mathworks Inc., Natick, 
Massachusetts, US.) as follows: 




The EEG data was pre-processed using Neuroscan software (v 4.5; Neuroscan, El Paso, 
Texas, USA) as follows: 
1. Bandpass filtered between 1 and 30 Hz (zero-phase shift filter with a slope of 24 
dB/octave) 
2. Epoched from 20 ms before the stimulus to 500 ms after 
3. Averaged across the stimulations 
4. Manually interpolating bad channels  
5. Average referenced 
Additionally the latency and peak to peak amplitudes of the highest stimulations was 
performed on single sweeps of the Oz electrode. In order to improve the signal-to-noise 
ratio a robust referencing scheme was applied using the early-stage EEG processing pipeline 
(PREP) (14) This was done within Matlab (R 2019a Mathworks Inc., Natick, Massachusetts, 
US.) and the EEGLAB toolbox (version 14.1.2, Swartz Center for Computational 
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Neuroscience, Institute for Neural Computation, University of California, San Diego, US.).  
After applying the PREP pipeline with standard settings the data was processed as follows: 
1. Bandpass filtered between 1 and 30 Hz (zero-phase shift filter with a slope of 24 
dB/octave) 
2. Epoched from 20 ms before the stimulus to 500 ms after 
3. Averaged across the high stimulations 
Feature extraction 
Electromyography 
All EMG analysis was performed on single sweeps, and quantified using the interval peak Z 
score, which reflects the highest peak in the rectified reflex window minus a baseline mean 





The reflex window was between 70 and 160 ms post stimulus and the baseline window was 
100 to 10 ms before the stimulation. In all cases a rectified AUC was calculated in the reflex 
window.  
If the Z score was above 12 it was interpreted as an NWR (16), and in the case where no part 
of the reflex window had a Z score above 12, the stimulation did not elicit an NWR. When 
successfully elicited, the latency was defined at the first time the rectified EMG trace had a 
Z-score above 12. 
Electroencephalography 
Early latency and amplitudes were identified and analysed at the Oz electrode due to its 
location in proximity to the brainstem. Since the early brainstem evoked potential is 
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normally referenced to an electrode placed above the jugular notch and the Oz electrode 
referenced to a cephalic reference the current studies N30 and P40 brainstem potential is 
an inverted image of the brainstem P30 N40 peak. 
Latencies and amplitude of SEP components were identified and analysed at the Cz 
electrode, because of its central location and maximal EP amplitude due to the electrical 
stimulation of the foot. The component consisted of the first and second positive peak (P1 
and P2) and the largest negative peak (N1).  
Statistical analysis 
Fisher's exact test was used to test if there was an association between the presence of DM 
and number of participants that could complete the stimulation session.  
A Mann–Whitney U test was used to compare changes between groups of the PT and RT, 
along with the peak-to-peak amplitude of the early evoked potential. 
A Mixed-effects logistic regression model was used to test the binary outcome NWR 
containing trials (yes/ no) against the group factor (DM vs healthy); categorical stimulation 
intensities (threshold, medium and high) and the random factor Subject ID. 
A mixed linear model was used to test differences in the latencies and AUC of the NWR, 
with group (DM vs healthy) as a between-subject factor, and the within-subjects factor 
stimulation intensity (threshold, medium and high).  
A Pearson’s correlation analysis was conducted to test the association of disease duration 
and latency of the P1 peak and amplitude of the N1 peak.  
A repeated measures mixed model was used to test the differences in the early latency with 
group (DM vs healthy) as a between-subject factor, and the within-subject factor peaks 
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(N30, P40), with subject as a random variable. 
Finally, a multivariate analysis of variance (MANOVA) with the independent factors (DM vs. 
healthy) was used with the Wilkes' lambda distribution to assess the dependent variables 
(amplitude and latency) of the peaks (P1 N1 P2) in the recorded EEG signals. If significant 
difference were seen, post hoc analyses was performed to interpret which component 
(positive or negative peak along with latency) contributed to the differences. The data was 
tested for normality using the Kolmogorov–Smirnov test for normality.  






In this study 48 participants with DM and DSPN were included and a group of 21 age 
matched healthy controls were recruited as a comparison; detailed demographics are 
shown in Table 1.  
 ------------------------------------------------ (Table 1) around here------------------------------------------- 
Nociceptive withdrawal reflexes 
Evaluation of perception and reflex threshold 
Compared to healthy subjects, people with DM had significantly increased PT (5 [2, 40] vs. 
3[2, 6] mA; p<0.001), the presence of DM also significantly increased the RT (22 [5, 50] vs. 
15 [6, 37] mA; p<0.012). For further analyses, only subjects who were able to complete the 
reflex recording were included. 
Evaluation of the ability to record the nociceptive withdrawal reflexes 
Compared to healthy subjects, the presence of DM reduced the numbers of participants 
(34/48 vs 21/21) in whom an NWR was successfully elicited (p<0.004).  
Evaluation of the ability to evoke the nociceptive withdrawal reflexes 
The presence of DM reduced the odds ratio (0.045 [0.004, 0.54]) of a successful elicited 
NWR; (p=0.014). An increased odds ratio (1.07 [1.018, 1.131]) of eliciting a NWR was shown 
with increasing stimulus intensities (p=0.009).  
----------------------------------------------- (Figure 2) around here -------------------------------------------- 
Description of the nociceptive withdrawal reflex 
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When the NWR could be elicited, no significant differences between the two groups (DM, 
Healthy) for latency (DM; p=0.168; 95% CI [-3.94, 22.7]) and AUC (DM; p=0.081; 95% CI [-
14.38, 0.84]) were shown. There was, however, a significant longer latency for lowest and 
medium stimulation intensities compared to the high intensity (threshold; p<0.001 95% CI 
[5, 12], medium; p<0.001 95% CI [3, 9]) and a significant lower AUC for the lowest and 
medium stimulation intensities compared to the high intensity (threshold; p<0.00 95% CI [-
9.64, -5.84] medium; p<0.00 95% CI [-5.8, -2]) A grand average EMG for healthy controls and 
patients with diabetes can be seen in  
Figure 2. 
EEG 
----------------------------------------------- (Figure 3) around here -------------------------------------------- 
One healthy control, and two patients with DM were excluded from the EEG analysis due to 
poor data quality. A grand average EEG for healthy controls and patients with diabetes can 
be seen in Figure 3 
Effect of disease duration on severity of diabetic symmetrical polyneuropathy (DSPN) 
There is no significant correlation between disease duration of the people with DM and 
latency of the P1 peak (p > 0.32) and the N1 amplitude (p > 0.63). 
Somatosensory Evoked Potentials (SEPs) 
In comparison to the healthy controls, the presence of DM did not significantly change the 
latency of the SEP at Oz (p = 0.746, 95% CI [-5.3, 7.3]). The peak to peak amplitude also did 
not change between DM (median 1.91) vs. healthy (median 2.24) (p > 0.95) 
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In comparison to healthy controls, the presence of DM significantly changed the SEP at Cz 
(F=2.86 p<0.025). Post-hoc test revealed changes of the N1 peak where amplitudes were 
reduced by -3.72 mV (p<0.021) and latencies were increased by +15.1 ms (p<0.013), 
detailed results are shown in Table 2. 




To our knowledge this paper is the first study which investigates both spinal and supra-
spinal responses to nociceptive withdrawal reflex stimulation in people with type-1 DM and 
DSPN and compare them to healthy controls. In the DM group the number of participants in 
whom NWR could be evoked was significantly smaller and the odds ratio of eliciting a NWR 
was reduced. In DM, the N1 peak measured at the vertex by EEG had decreased amplitude 
and prolonged latencies. The findings imply that DM induces widespread changes of both 
spinal and supra-spinal somatosensory signal processing. 
Diabetes induced changes at the peripheral and spinal level 
The differences in the elicited NWR in patients with DM could indicate demyelination of the 
A-δ fibers, since these are necessary for the activation of the NWR (17). DSPN typically 
affects the nerves in a length-dependent manner and therefore affects the feet and hands 
first (8), by demyelinating the nerve fibers, and consequently decreases the conduction 
velocity (18–20). The nerve conduction test mainly measures the thickly myelinated A-β 
fibres. Therefore, the current study, which measures the smaller A-δ fibres from the NWR 
(12,13) is complementary to classical nerve testing in understanding the widespread effects 
of DSPN. Small fibre neuropathy affects the thinner myelinated A-δ and unmyelinated C 
fibres without affecting the thicker myelinated fibres, and are therefore not diagnosed 
when using traditional conduction velocity tests (21). It should be stressed, however, that 
the reported changes of latency and AUC in this paper may be not be entirely representative 
for the DSPN population as it was not possible to elicit an NWR in all subjects.  
The EMG recordings of the anterior tibial muscle in response to an electrical stimulation 
investigates the input-output relationship of the stimulation, and the time it takes from the 
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stimulus to an NWR is evoked (i.e. from the sole of the foot through the spinal reflex 
pathway to activation of the muscle), and the size of the response in the muscle. These 
measures characterize the nature of the NWR arch and thus also a part of the spinal 
pathway.  
The difficulties in recording the NWR in DM are plausibly due to DM induced neuropathy, 
which is supported by a previous study in which the NWR could only be recorded in three 
out of seven (43%) of the included diabetes patients with DSPN (22). Recently, the method 
used to elicit the NWR of the anterior tibial muscle compared to the traditionally used 
biceps femoris has been found equally reliable at measuring the NWR and the choice of 
measuring reflexes at anterior tibial muscle is recommended in clinical trials due to the 
lower perception of pain (23). 
Diabetes induced changes at the supra-spinal level 
In order to investigate the responses at the supra-spinal level we aimed at estimating the 
afferent input in order to rule out any differences of the upstream activation, as this could 
explain any changes in the supra-spinal recordings. However, in this study we found no 
significant differences in the early evoked potentials recorded at Oz close to the brainstem, 
indicating that the afferent input was not significantly different between groups. At the Cz 
electrode (at the vertex), in contrast, DM did cause a significant decrease of the N1 
amplitude and increase of latency in the recorded EEG signal. The P1 component at the 
vertex reflects exogenous processing of the primary somatosensory cortex activity and thus 
is insensitive to stimulus intensity and perceived pain. The endogenous components at the 
vertex appears 100 ms post-stimulus (N1 and P2), and increase with pain intensity (24). The 
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differences in the N1 component between groups indicate altered responses of the later 
cortical signal. 
It is plausible that the evoked potentials are associated to disease duration and thereby 
hyperglycemic exposure to the axons. However, our findings indicate that no such 
association is found within this group of subjects. This may be explained by several factors: 
Firstly, it is generally accepted that disease duration in itself does not explain the 
progression of neuropathy, it is most likely doe to the number of events of hypo- and 
hyperglycemia that induces neurotoxicity, especially in well regulated cases (25). Secondly, 
this cohort may be vulnerable to selection bias, since they all had long disease duration and 
verified distal symmetrical polyneuropathy, and therefore represent a homogeneous group, 
which may hamper a true association between disease duration and EP´s. 
In contrast to MRI studies which can detect both structural and functional neuronal changes 
in response to DM with/without painful DSPN (26–30). This electrophysiological study does 
not allow such interpretation, as pain is the conscious interpretation of the nociceptive 
input, which is continuously influenced by multiple cortical regions (31). The alterations of 
the neuronal responses in DM in the current study reflects altered activation of 
somatosensory processing, it is not possible to determine if there are any changes to the 
pain matrix given the current experimental setup (32).   
EEG studies have found significant changes in the integrity of the processing of resting EEG 
and somatic and visceral elicited EP´s, (33–36), and taken together the complementary 
techniques mentioned above supports the current findings.  
One study has shown that NWR´s elicited with intensities below RT (sub-RT) lead to 
increased amplitude of the SEP associated to the stimulation intensity, however amplitudes 
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were not significant different when stimulation intensities were chosen at or above RT (37). 
Consequently, the concomitantly recorded EEG during NWR in each subject were averaged 
across stimulation intensities to optimize signal-to-noise ratios.  
Limitations 
This study was not conducted without limitations. Firstly, the recruitment was vulnerable to 
selection bias as in particularity individuals with a surplus of resources, might be 
overrepresented. Nevertheless, all patients had verified type-1 DM and DSPN. Recordings 
were however only completed in a sub-group which increases the risk of a type-II error and 
limits the external validity, and thus our findings should be interpreted cautiously. 
Furthermore, the results within this paper do not relate to all people with DM, since no 
subjects with DM, but without DSPN, were included.   
Secondly, the use of a calculated Z-score produces a binary outcome of the reflex.  The Z-
score is susceptible to poor signal to noise ratio, and thus true NWR may have been 
discarded due to high level of biological/electrical noise. The choice of a threshold of 12 
yields a high true positive rate, but also carries the risk of false negatives (15). However, it is 
an objective and reliable method of detecting the presence of a successful elicitation of an 
NWR, and as such not hampered by subjective interpretation. Thirdly, the use of 
interpreting EP´s at the Oz electrode reveals that no differences occur at the 
spinal/brainstem level, however we cannot determine the central alterations based on 
interpretation of the Cz alone. 
In conclusion the study revealed that patients with type-1 diabetes and DSPN have 
significantly changed spinal and supraspinal processing of the somatosensory input.  This 
implies that DSPN induces widespread differences in the central nervous system processing 
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of afferent A-δ and A-β fiber input. These differences in processing may potentially lead to 
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Figure 1 Visual representation of the data analysed within this study. Not all patients were 
able to complete the experimental procedure. Two patients with diabetes and one healthy 
control was excluded from the somatosensory evoked potential due to poor signal to noise 
ratio.  
Figure 2. Grand average of all data of rectified EMG traces of the nociceptive withdrawal 
reflex with a z-score above 12, the shaded area is the 95% confidence interval. The reflex 
window (70-160 ms. after the electrical stimulation) is the area in which the area under the 
curve (AUC) of the single sweep reflex is calculated. Time 0 is when the electrical stimulation 
was applied to the skin of the plantar side of the foot. 
Figure 3 Grand average of healthy controls and patients with diabetes at the Cz electrode 
location, the shaded area is the 95% confidence interval. Time 0 is when the electrical 





























1 Withdrew because pain became too unbarable
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Grand averages of the nocicep�ve withdrawal reflex 
Cz
Table 1:  Demography    
 Healthy (n = 21) Diabetes (n = 48) p-value 
Age (years) 51.3 (6.4; 40-62) 50.0 (8.5; 33-71) 0.53 
Gender 6 female. 15 males 9 female. 39 males 0.48 
Height (cm) 179.8 (9.0; 158-192) 178.4 (8.6; 158-192) 0.55 
Weight (kg) 87.3 (20.5; 62-140) 90.0 (16.0; 63-132) 0.56 
BMI (kg/m2) 
Conduction velocity  
sural nerve (m/s) 
26.9 (5.5; 21-40) 
49.67 (6.06; 40-66) 
28.5 (4.9; 22-43) 
42.17 (5.84; 32-60) 
0.30 
<0.001 
Disease duration (years) -- 32.2 (9.5; 14-51)  
All statistical analysis is performed using t-test. Average (SD; range). P-values<0.05 
indicate significant differences 
 
Table 2: Assessment of evoked potentials at three different points 
Electrode Healthy (n  = 20) Diabetes (n = 32) Difference p-value Post-hoc 
Cz    0.024  
     P1 latency (ms) 61.5 (9.27) 58.21 (14.45) 3.29  p=0.240 
     N1 amplitude (V) 15.59 (4.82) 11.87 (5.83) 3.72  p=0.021 
     N1 latency (ms) 146.15 (16.43) 161.25 (22.81) -15.1  p=0.013 
     P2 amplitude (V) 7.4 (5.52) 6.28 (4.84) 1,12  p=0.739 
     P2 latency (ms) 280.5(36.7) 284.85(38.7) -4,35  p=0.448 
The outcome of the MANOVA and subsequent post hoc test. Numbers are reported in average 
(SD) 
 
